Clinical Significance of Tumor Infiltrating Lymphocytes in Association with Hormone Receptor Expression Patterns in Epithelial Ovarian Cancer by 김재훈 et al.
 International Journal of 
Molecular Sciences
Article
Clinical Significance of Tumor Infiltrating Lymphocytes in
Association with Hormone Receptor Expression Patterns in
Epithelial Ovarian Cancer
Gwan Hee Han 1,2 , Ilseon Hwang 3,4, Hanbyoul Cho 1,3,5,6 , Kris Ylaya 3, Jung-A Choi 5, Hyunja Kwon 5,
Joon-Yong Chung 3 , Stephen M. Hewitt 3 and Jae-Hoon Kim 1,5,6,*


Citation: Han, G.H.; Hwang, I.;
Cho, H.; Ylaya, K.; Choi, J.-A;
Kwon, H.; Chung, J.-Y.; Hewitt, S.M.;
Kim, J.-H. Clinical Significance of
Tumor Infiltrating Lymphocytes in
Association with Hormone Receptor
Expression Patterns in Epithelial





Received: 18 April 2021
Accepted: 21 May 2021
Published: 27 May 2021
Publisher’s Note: MDPI stays neutral
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
Copyright: © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).
1 Department of Obstetrics and Gynecology, Yonsei University College of Medicine, Seoul 03722, Korea;
lachicabona@gmail.com (G.H.H.); hanbyoul@yuhs.ac (H.C.)
2 Department of Obstetrics and Gynecology, Kyung Hee University Hospital at Gangdong, Seoul 05278, Korea
3 Experimental Pathology Laboratory, Laboratory of Pathology, Center for Cancer Research, National Cancer
Institute, National Institutes of Health, Bethesda, MD 20892, USA; ilseon.hwang@gmail.com (I.H.);
ylayakri@mail.nih.gov (K.Y.); chungjo@mail.nih.gov (J.-Y.C.); genejock@helix.nih.gov (S.M.H.)
4 Dongsan Medical Center, Department of Pathology, Keimyung University School of Medicine,
Daegu 42601, Korea
5 Department of Obstetrics and Gynecology, Gangnam Severance Hospital, Yonsei University College of
Medicine, Seoul 06229, Korea; jachoi@yuhs.ac (J.-A.C.); 89hjkwon@hanmail.net (H.K.)
6 Institute of Women’s Life Medical Science, Yonsei University College of Medicine, Seoul 03722, Korea
* Correspondence: jaehoonkim@yuhs.ac; Tel.: +82-2-2019-3430; Fax: +82-2-3462-8209
Abstract: Hormone receptor expression patterns often correlate with infiltration of specific lympho-
cytes in tumors. Specifically, the presence of specific tumor-infiltrating lymphocytes (TILs) with
particular hormone receptor expression is reportedly associated with breast cancer, however, this
has not been revealed in epithelial ovarian cancer (EOC). Therefore, we investigated the association
between hormone receptor expression and TILs in EOC. Here we found that ERα, AR, and GR expres-
sion increased in EOC, while PR was significantly reduced and ERβ expression showed a reduced
trend compared to normal epithelium. Cluster analysis indicated poor disease-free survival (DFS) in
AR+/GR+/PR+ subgroup (triple dominant group); while the Cox proportional-hazards model high-
lighted the triple dominant group as an independent prognostic factor for DFS. In addition, significant
upregulation of FoxP3+ TILs, PD-1, and PD-L1 was observed in the triple dominant group compared
to other groups. NanoString analyses further suggested that tumor necrosis factor (TNF) and/or
NF-κB signaling pathways were activated with significant upregulation of RELA, MAP3K5, TNFAIP3,
BCL2L1, RIPK1, TRAF2, PARP1, and AKT1 in the triple dominant EOC group. The triple domi-
nant subgroup correlates with poor prognosis in EOC. Moreover, the TNF and/or NF-κB signaling
pathways may be responsible for hormone-mediated inhibition of the immune microenvironment.
Keywords: epithelial ovarian cancer; hormone receptors; triple dominant group; tumor infiltrating
lymphocytes; regulatory T cell
1. Introduction
Epithelial ovarian cancer (EOC) is one of the most lethal gynecologic malignancies,
responsible for more than 100,000 cancer-related deaths annually, worldwide [1]. The
majority of patients are diagnosed at an advanced stage because of the lack of specific
symptoms and effective cancer screening methods at the early stages. To date, the stan-
dard treatment for EOC is primary cytoreductive surgery followed by platinum-based
chemotherapy. However, most patients experience relapse within 2 years and develop
chemotherapy resistance. Emerging evidence has highlighted the potential of targeted ther-
apies, such as anti-angiogenic therapy with bevacizumab or poly (ADP-ribose) polymerase
(PARP) inhibitors. However, their contribution toward improving survival and prognosis
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remains modest [2]. Although current clinical trials on single-agent programmed cell death
protein 1 (PD-1) blockade demonstrated promising results in EOC treatment, the overall
response rate is considerably lower than that achieved in melanoma, lung cancer, and renal
cell cancer [3].
Many studies have identified EOC as an immunogenic tumor, recognizable by the
host immune system [4]. Therefore, evaluating the tumor-infiltrating lymphocytes (TILs) in
EOC has recently gained attention [5,6]. TILs are the type of white blood cells present in the
tumor islets and stroma that recognize tumor cells and elicit an immune response. In EOC,
CD8+, CD4+ T-helper 1 (Th1), and natural killer (NK) cells reportedly participate in tumor
suppression responses, whereas CD4+ T-helper 2 (Th2), FoxP3+ T-regulatory (Treg), and
dendritic cells contribute to immunosuppression [7]. However, the activity and presence
of TILs can be modulated by many factors, including endocrine and proinflammatory
molecules. Estrogen receptor (ER)α influences cancer development by regulating cellular
development and differentiation, whereas ERβ prevents EOC development. Accumulating
evidence suggests that the androgen receptor (AR) is associated with the progression and
development of EOC [8]. Moreover, at low concentrations, the progesterone receptor (PR)
stimulates EOC progression, while suppressing it at high concentrations [9–12]. As nearly
all immune cells express hormone receptors, and several immune-related genes possess
AR and ER response elements in their promoters, hormone receptors can modulate B cell,
T cell, macrophage, neutrophil, and NK cell behaviors [13–17]. Indeed, studies on the
breast cancer tumor microenvironment (TME) suggest that hormone receptor-positive
breast tumors may be immunologically “colder” than their triple-negative and human
epidermal development element receptor 2 (HER2)-positive counterparts [18]. These
observations suggest that hormone receptors influence the expression of genes in TILs in
cancers. However, little is known regarding the expression of genes in TILs in relation to
specific hormone receptor expression profiles in EOC.
EOC is a highly heterogeneous disease, and emerging evidence suggests that targeted
therapy is applicable based on subgroup-specific prognostic and predictive biomarkers.
Therefore, we aimed to comparatively analyze the relationships between the properties of
TILs and hormone receptor expression patterns in EOC. Furthermore, we aimed to evaluate
the usefulness of a subgroup-specific prognostic biomarker for immunotherapy.
2. Results
2.1. Expression of Hormone Receptors in EOC Tissues
The representative IHC results for ERα, AR, GR, PR, and ERβ are shown in Figure 1A,
and IHC scores are summarized in Supplementary Table S1 and Figure 1B. The data showed
significantly higher expression of ERα, AR, and GR in EOCs than in nonadjacent normal
epithelial tissues (p = 0.001, p < 0.001, p < 0.001; respectively; Supplementary Table S1 and
Figure 1B). Conversely, PR expression was significantly lower in EOCs than in nonadjacent
normal epithelial tissues (p = 0.005; Supplementary Table S1 and Figure 1B). Although not
significant, ERβ expression tended to be low in EOCs was compared to that in nonadjacent
normal epithelial tissues (p = 0.144; Supplementary Table S1 and Figure 1B). Next, we con-
firmed the expression levels of ERα, AR, PR, and ERβ hormone receptors using a publicly
available dataset, which showed good agreement with the trends observed in our study
(Figure 1C). However, GR expression showed the opposite result, and ERβ expression did
not show any significant differences, which might be due to differences in protein stabil-
ity which has been extensively studied in hormone receptors [19]. We then investigated
clinicopathological characteristics based on hormone receptor expression patterns. The im-
munoreactivity of ERα and PR was significantly associated with serous cell type (p = 0.027,
p = 0.008, respectively; Supplementary Table S1), and AR overexpression significantly cor-
related with positive CA125 (p = 0.024; Supplementary Table S1). In addition, ERβ and GR
overexpression were significantly associated with early (p = 0.047; Supplementary Table S1)
and advanced FIGO stage (p = 0.050; Supplementary Table S1), respectively.
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Next, we examined the relationship between hormone receptor expression and DFS
and OS in patients with EOC using Kaplan–Meier plots. Results showed that ERα or GR
overexpression correlated with poor DFS (p = 0.032, p = 0.025, respectively; Figure 1D)
and OS (p = 0.002, p = 0.017, respectively; Figure 1E). On the contrary, ERβ overexpression
significantly correlated with improved DFS and OS (p = 0.003, p = 0.048, respectively;
Figure 1D,E). AR overexpression significantly correlated with poor DFS, whereas AR
overexpression showed a statistically non-significant correlation with better OS (p = 0.002,
p = 0.089, respectively; Figure 1D,E). Notably, PR expression was lower in EOCs than in
nonadjacent normal epithelial tissues; however, its overexpression in EOCs showed a trend
toward poor DFS (p = 0.384; Figure 1D).
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Figure 1. Expression of hormone receptors in EOC tissues. (A) Representative immunohistochemical staining images of 
ERα, AR, PR, GR, and ERβ in nonadjacent ovarian epithelial tissues (Normal) and epithelial ovarian cancer (Cancer) tissue 
samples (scale bar: 50 μm). (B) Boxplots of IHC staining data (histoscores) comparing between nonadjacent ovarian epi-
thelial tissues (Normal) and epithelial ovarian cancer (Cancer) tissue samples of each hormone receptor subtype. His-
toscores were calculated based on staining intensity and the area of positive staining (C) Publicly available data on the 
mRNA expression of ERα, AR, PR, GR, and ERβ were obtained from the GEO data (GSE26712). A Mann–Whitney U-test 
or Kruskal–Wallis test was used to compare the mRNA expression level of each hormone receptor. (D) The DFS of patients 
with EOC depends on ERα, AR, PR, GR, and ERβ expression. For the DFS analysis, 189 patients with EOC for ERα, 175 
patients with EOC for AR, 189 patients with EOC for PR, 190 patients with EOC for GR, and 187 patients with EOC for 
ERβ were included. (E) The OS of patients with EOC depends on ERα, AR, PR, GR, and ERβ expression. For the OS 
analysis, 189 patients with EOC for ERα, 175 patients with EOC for AR, 189 patients with EOC for PR, 190 patients with 
EOC for GR, and 187 patients with EOC for ERβ were included. The cut-off value of ERα was over 49.2 of the IHC score, 
cut-off value of AR was over 10.85 of the IHC score, cut-off value of PR was over 21.18 of the IHC score, and the cut-off 
value of GR was over 8.65 of the IHC score. 
2.2. Hierarchical Clustering Analysis of Hormone Receptors in EOCs 
EOC was categorized into three different subgroups: triple dominant 
(AR+/PR+/GR+), GR-dominant, and PR-dominant, using hierarchical clustering analysis, 
which was performed to identify subgroups based on hormone receptor expression pat-
terns related to prognosis after evaluating the clinicopathological characteristics based on 
a single hormone receptor (Figure 2A and Supplementary Figure S1A). The triple domi-
nant group was significantly associated with a more advanced FIGO stage and serous cell 
type and poor grade compared with GR- or PR-dominant groups (p = 0.015, p = 0.042, p = 
0.042, respectively; Supplementary Figure S1B). Moreover, we observed that the triple 
dominant group was significantly associated with poor DFS (p < 0.001; Figure 2B). Cox 
multivariate proportional-hazards analysis further revealed that the triple dominant 
Figure 1. Expression of hormone receptors in EOC tissues. (A) Representative immunohistochemical staining images
of ERα, AR, PR, GR, and ERβ in nonadjacent ovarian epithelial tissues (Normal) and epithelial ovarian cancer (Cancer)
tissue samples (scale bar: 50 µm). (B) Boxplots of IHC staining data (histoscores) comparing between nonadjacent ovarian
epithelial tissues (Normal) and epithelial ovarian cancer (Cancer) tissue samples of each hormone receptor subtype.
Histoscores were calculated based on staining intensity and the area of positive staining (C) Publicly available data on
the mRNA expression of ERα, AR, PR, GR, and ERβ were obtained from the GEO data (GSE26712). A Mann–Whitney
U-test or Kruskal–Wallis test was used to compare the mRNA expression level of each hormone receptor. (D) The DFS of
patients with EOC depends on ERα, AR, PR, GR, and ERβ expression. For the DFS analysis, 189 patients with E C for ERα,
175 patients with EOC for AR, 189 patients with EOC for PR, 190 patients with EOC for GR, and 187 patients with EOC
for ERβwere included. (E) The OS of patients with EOC depends on E , , PR, GR, and ERβ expression. For the OS
analysis, 189 patients with EOC for ERα, 175 patients it for AR, 189 patients with EOC for PR, 190 patients with
EOC for GR, and 187 patients with EOC for ERβwere incl e . e cut-off value of ERαwas over 49.2 of the IHC score,
cut-off value of AR was over 10.85 of the IHC score, cut- ff l e of PR was over 21.18 of the IHC score, and the cut-off
value of GR was over 8.65 of the IHC score.
2.2. Hierarchical Clustering Analysis of Hormone Receptors in EOCs
EOC was categorized into three different subgroups: triple dominant (AR+/PR+/GR+),
GR-dominant, and PR-dominant, using hierarchical clustering analysis, which was per-
formed to identify subgroups based on hormone receptor expression patterns related to
prognosis after evaluating the clinicopathological characteristics based on a single hor-
mone receptor (Fi ure 2A and Supplemen ary Figure S1A). The triple dominant group
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was significantly associated with a more advanced FIGO stage and serous cell type and
poor grade compared with GR- or PR-dominant groups (p = 0.015, p = 0.042, p = 0.042,
respectively; Supplementary Figure S1B). Moreover, we observed that the triple dominant
group was significantly associated with poor DFS (p < 0.001; Figure 2B). Cox multivariate
proportional-hazards analysis further revealed that the triple dominant group was an
independent prognostic factor for poor DFS (HR = 2.176, 95% CI = 1.361–3.487; p = 0.001;
Table 1). Notably, only the triple dominant group showed statistical significance in Cox
multivariate proportional-hazards analysis compared with the groups with single domi-
nant hormone receptors (Table 1). Moreover, we performed separate subgroup analyses in
the triple, GR-, and PR-dominant groups (Figure 2C). Survival analysis showed that triple,
GR-, and PR-dominant groups were significantly associated with poor DFS in patients at a
more advanced stage, who developed platinum resistance (p = 0.009, p < 0.001, p = 0.002,
p < 0.001, p < 0.001, p < 0.001, respectively; Figure 2C). The subgroup analysis results with
respect to cell type, grade, and positive CA125 are presented in Supplementary Figure S2.
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PR-dominant group. Forty-eight patients with EOC in the triple dominant group and 148 patients 
with EOC in the GR- or PR-dominant group were included. (C) Subgroup DFS analysis in the tri-
ple dominant group was based on the FIGO stage and platinum sensitivity (n = 196). 
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Age (>50) 1.577 [1.064–2.339] 0.023 1.231 [0.810–1.872] 0.330 
ERα + a 1.625 [1.038–2.542] 0.034 1.363 [0.842–2.207] 0.207 
Figure 2. Hierarchical clust ing analysis of hormone receptor xpression in EOCs. (A) Hierarchical clustering analysis of
all patient samples in which staining for all five receptors was performed. On the left, the three subgroups identified using
the clustering analysis are indicated. Vertically, the expression of different receptors is depicted: orange indicating positive
expression and purple indicating negative expression. Color scaling was based on the semi-quantitative immunoscores.
(B) DFS and OS of patients with EOC between the triple dominant group and GR- or PR-dominant group. Forty-eight
patients with EOC in the triple dominant group and 148 patients with EOC in the GR- or PR-dominant group were included.
(C) Subgroup FS analysis in the triple dominant group was based on t e FIGO stage and platinum sensitivity (n = 196).
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Table 1. Univariate and multivariate analyses of the association between prognostic variables and disease-free survival
rates in epithelial ovarian cancer.
Variables
Univariate Analysis Multivariate Analysis
Hazard Ratio [95%CI *] p-Value Hazard Ratio [95%CI *] p-Value
FIGO stage (III-IV) 6.427 [3.335–12.386] <0.001 4.604 [2.260–9.380] <0.001
Cell type (Serous) 0.337 [0.202–0.561] <0.001 0.525 [0.294–0.939] 0.030
Tumor grade (Poor) 1.949 [1.286–2.954] 0.002 1.646 [1.074–2.518] 0.022
CA 125 + (>35 U/mL) 2.397 [1.208–4.753] 0.012 1.004 [0.471–2.141] 0.992
Age (>50) 1.577 [1.064–2.339] 0.023 1.231 [0.810–1.872] 0.330
ERα + a 1.625 [1.038–2.542] 0.034 1.363 [0.842–2.207] 0.207
AR + b 1.887 [1.245–2.860] 0.002 1.546 [0.998–2.396] 0.051
PR + c 1.201 [0.794–1.815] 0.386 NA
GR + d 2.610 [1.143–5.958] 0.023 1.892 [0.823–4.351] 0.133
ERβ + e 1.824 [1.226–2.714] 0.003 1.403 [0.918–2.543] 0.118
Heatmap
(Triple dominant) 2.668 [1.728–4.118] <0.001 2.176 [1.361–3.487] 0.001
a cut-off value of ERα is over 49.2 of IHC score; b cut-off value of AR is over 10.85 of IHC score; c cut-off value of PR is over 21.18 of IHC
score; d cut-off value of GR is over 8.65 of IHC score; e cut-off value of ERβ is over 105.97 of IHC score; * CI, confidence interval; FIGO,
International Federation of Gynecology and Obstetrics; NA: Not available.
2.3. Association between TIL Infiltration and EOC Subgroups Based on Hormone Receptors
Considering the importance of hormone receptors in the prognosis of EOC, we hypoth-
esized that they contribute to the behavior of TILs, as the nuclear factor (NF)-κB pathway is
involved in both hormone receptor signaling and TIL biology [20–23]. Before verifying this
hypothesis, we first evaluated the expression of CD4+, CD8+, CD3+, and FoxP3+ in whole
tissue sections of the EOC. Representative images of IHC staining are shown in Figure 3A,
and the clinicopathological characteristics are presented in Supplementary Table S2. The
prognostic significance of specific subtype of infiltrating TILs and their ratio showed that a
high infiltration of FoxP3+ TILs was associated with poor DFS and OS (p = 0.011, p < 0.001,
respectively; Figure 3B) and increased CD3+/FoxP3+ ratio was associated with favorable
DFS and OS (p = 0.049, p = 0.011, respectively; Figure 3B). We further analyzed whether
hormone receptor expression might influence the behavior of TILs in EOC and found
that FoxP3+ TILs were significantly more abundant in the triple dominant group than in
GR- and PR-dominant groups (p = 0.014; Figure 3C). In addition, the CD3+/FoxP3+ ratio
significantly decreased in the triple dominant group (p = 0.070, Figure 3C).
2.4. Association between PD-1 or Programmed Cell Death Protein-Ligand1 (PD-L1) Expression
and EOC Subgroups Based on Hormone Receptors
As recognizing FoxP3+ alone does not sufficiently define Tregs, we also performed
a similar analysis to determine the association between PD-1 or PD-L1 expression and
the triple dominant group, a subgroup of EOC. Before verifying their association, we first
evaluated PD-1 or PD-L1 expression in EOC. A representative IHC image is shown in
Figure 3D, and clinicopathological characteristics are presented in Supplementary Table S2.
Neither PD-1 nor PD-L1 revealed a significant association with DFS (p = 0.322, p = 0.069,
respectively; Figure 3E) or OS (p = 0.309, p = 0.201, respectively; Figure 3E). Importantly,
when evaluating the association between the triple dominant group and PD-1, and PD-L1
expression, we observed a significantly upregulated PD-1 and PD-L1 expression compared
with that of other groups (p = 0.036, p = 0.044, respectively; Figure 3F).
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observed in cancer stroma (scale bar: 100 μm). (B) DFS and OS of patients with EOC were based 
on FoxP3+ TIL infiltration level and CD3+/FoxP3+ ratio. (C) A boxplot of FoxP3+ TIL infiltration 
Figure 3. PD-1 and PD-L1 expression in EOC and their association with tumor-infiltrating lymphocytes and EOC subgroups
clustered by hormone receptor expression pattern. (A) Representative immunohistochemical images of CD4+, CD8+, CD3+,
and FoxP3+ TILs in EOCs. The TILs were observed in cancer stroma (scale bar: 100 µm). (B) DFS and OS of patients with
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EOC were based on FoxP3+ TIL infiltration level and CD3+/FoxP3+ ratio. (C) A boxplot of FoxP3+ TIL infiltration level
or CD3+/FoxP3+ ratio and subgroups clustered by hormone receptor expression pattern. (D) Representative immuno-
histochemical images of PD-1 and PD-L1 levels in EOCs (scale bar: 100 µm). (E) The DFS and OS of patients with EOC
were based on PD-1 and PD-L1 expression. (F) A boxplot of TIL infiltration with PD-1 or PD-L1 expression in subgroups
clustered by hormone receptor expression pattern in EOC.
2.5. NanoString Analysis of the Triple Dominant Group
We then analyzed the DEGs with mRNA extracted from six normal ovarian epithelial
tissues and six EOC tissues in the triple dominant EOC group to gain insight into the
molecular details of the triple dominant group [24]. A total of 228 upregulated DEGs
were identified with an adjusted p-value cut-off of 0.05 (Figure 4A, Supplementary Table
S3). Expectedly, several upregulated genes were classified as cytokine-related genes. To
gain further biological insights, we constructed ovarian tissue-specific PPI networks using
NetworkAnalyst [25] with the identified upregulated DEGs (n = 169). The results showed
that γ-rel avian reticuloendotheliosis viral oncogene homolog A (RELA), mitogen-activated
protein kinase 5 (MAP3K5), tumor necrosis factor α-induced protein 3 (TNFAIP3), BCL2-
like protein 1 (BCL2L1), receptor-interacting protein kinase 1 (RIPK1), tumor necrosis factor
receptor-associated factor 2 (TRAF2), PARP1, and v-akt murine thymoma viral oncogene
homolog 1 (AKT1) were the most highly connected genes in the minimum-order network
(Figure 4B). Moreover, RELA, MAP3K5, and TNFAIP3 showed the highest connection in
the zero-order network (Figure 4C,D). Gene Ontology analysis of the network components
also indicated that genes involved in the TNF (adjusted p-value < 2.16 × 10−38) and/or
NF-κB (adjusted p-value < 6.17 × 10−27) signaling pathways were significantly enriched
with respect to the upregulated DEGs (Figure 4E). Overall, the DEG and PPI network
analyses indicated that RELA, MAP3K5, TNFAIP3, BCL2L1, RIPK1, TRAF2, PARP1, and
AKT1 profoundly influenced the triple dominant group of EOC through the TNF and/or
NF-κB signaling pathways. We also conducted a comprehensive Gene Ontology analysis
using g:profiler [26] to analyze the enriched pathways in the triple dominant group of EOC.
As expected, many genes were found to be involved in cytokine signaling and the immune
system (cytokine receptor binding (adjusted p-value < 2.44× 10−87), chemokine activity (ad-
justed p-value < 1.31 × 10−32), immune receptor activity (adjusted p-value < 3.77 × 10−12),
and chemokine-mediated signaling pathway (adjusted p-value < 7.10 × 10−38), (Figure 4E
and Supplementary Table S4). Interestingly, we found that some pathways were related
to the differentiation of Treg such as positive regulation of T cell activation (adjusted
p-value < 2.36 × 10−27), selective expression of chemokine receptors during T cell polar-
ization (adjusted p-value < 1.62 × 10−18), and interleukin-2 signaling pathway (adjusted
p-value < 7.69 × 10−23) (Figure 4E and Supplementary Table S4). Moreover, enrichment of
interleukin-1 receptor binding (adjusted p-value < 1.22 × 10−30), response to lipopolysac-
charide (adjusted p-value < 7.21 × 10−51), interleukin-4 and interleukin-13 signaling (ad-
justed p-value < 2.10 × 10−36), interleukin-10 signaling (adjusted p-value < 2.29 × 10−33),
toll-like receptor cascades (adjusted p-value < 3.18 × 10−25), and apoptosis (adjusted p-
value < 6.67 × 10−14) which were responsible for modulating Treg functions were upregu-
lated in the triple dominant group (Figure 4E and Supplementary Table S4). Overall, this
finding indicates that the triple dominant group activates host immune system and con-
tributes to the expansion and differentiation of Treg FoxP3+ lymphocytes (Supplementary
Table S4) [27–29].
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Figure 4. Analysis of differentially expressed genes (DEGs) in the triple dominant EOC group as compared to gene
expression in normal ovarian epithelial tissues. Analysis of differentially expressed genes (DEGs) in the triple dominant
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EOC group compared with gene expression in normal ovarian epithelial tissues. (A) Volcano plot shows the upregulated
DEGs in the triple dominant EOC group compared with gene expression in normal ovarian epithelial tissues. (B) Minimum-
order and (C) zero-order protein-protein interaction (PPI) network was constructed with 167 upregulated DEGs using
NetworkAnalyst (https://www.networkanalyst.ca/, accessed on 15 December 2020) (D) Genes with a higher number of
PPI interactions are listed. (E) Most significantly upregulated pathways identified in the PPI networks are shown using
Heatmap and volcano plot. (F) g:Profiler (https://biit.cs.ut.ee/gprofiler/, accessed on 15 December 2020) was used to
dissect molecular pathways of 167 upregulated DEGs in the triple dominant EOC group compared with gene expression in
normal ovarian epithelial tissues with the following categories: [GO:MF—molecular function; GO:BP—biologic process;
GO:CC—cellular component; KEGG—Kyoto Encyclopedia of Genes and Genomes; REAC—reactome; WP—Wikipathways;
TF—TRANSFAC; miRNA—miRTarBase; HPA—human protein atlas; CORUM—CORUM protein complexes; HP—human
phenotype ontology].
3. Discussion
The endocrine organs and hormone receptor expression may be associated with the
occurrence, progression, and overall prognosis of EOC. However, previous studies have
primarily focused on investigating the prognostic value of a single hormone receptor.
Although Feng et al. [30] and Kruchten et al. [31] performed cluster analysis over a single
isoform of hormone receptors, their results were less conclusive. Moreover, studies involv-
ing cluster analysis using steroid hormone receptors, such as GR and AR, in addition to
ERα, PR, and ERβ in EOC, are lacking. Meanwhile, herein we demonstrated that the triple
dominant (AR+/PR+/GR+) subgroup represents an independent prognostic factor in the
multivariate analysis, whereas groups with single dominant steroid hormone receptors did
not yield significant results. Taken together, our results suggest that the triple dominant
subgroup may play an important role in predicting the treatment and prognosis of EOC.
Interestingly, we found an association between PR activity and EOC prognosis. In
general, PR is considered a good prognostic factor for EOC. However, its activity was
altered based on which hormone receptors were simultaneously expressed. For example,
in the triple dominant subgroup where GR and AR were co-expressed, PR overexpression
was associated with poor prognosis, unlike in the PR- or GR-dominant subgroups of
EOC (Supplementary Figure S3). Similarly, PR activation is associated with the increased
occurrence and progression of breast cancer, whereas GR is related to growth suppression
and differentiation. Ogara et al. [32] reported that GR negatively regulates PR activity by
modulating PR target genes, as GR and PR share structural and functional similarities. They
also suggested that GR-PR heterocomplex formation increases negative regulation of PR
activity [33]. In addition to PR, GR regulates the expression of AR target genes, while AR
and PR have 88% sequence homology [34,35]. Therefore, we hypothesized that GR might
modulate both AR and PR directly and indirectly. The role of hormone receptor crosstalk
in cancer is becoming increasingly relevant, although the mechanisms involved remain
controversial, particularly in EOC. Thus, our findings suggest the possibility of different
transcriptional outcomes for the triple dominant group in EOC. Further investigation
in this regard could explain the prognosis associated with the triple dominant group in
more detail and contribute to the development of new endocrine combined therapies in
the future.
To date, several studies on EOC have reported that an elevated number of Tregs signif-
icantly correlates with a worse prognosis [36]. Nevertheless, evaluating TILs in the context
of hormone receptors is important as altered expression of hormones and their cognate
receptors represent mediators of immune trafficking and inflammatory processes affecting
the TME. For instance, several important mechanisms modulated by GR related to apopto-
sis and differentiation and proliferation of Tregs have been reported. One such mechanism
involves GR enhancing the expression of immunosuppressive cytokines, IL-10 and TGF-β,
which are capable of subsequently augmenting FoxP3+ expression [37,38]. Furthermore,
Huang et al. [39] reported that simultaneous overexpression of BCL-2 and GR effectively
inhibits glucocorticoid-dependent apoptosis of Tregs. Moreover, Bereshchenko et al. [40]
demonstrated that following its translocation to the nucleus, GR induces glucocorticoid-
induced leucine zipper (GILZ) production, a protein induced by glucocorticoid, as well
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as enhanced FoxP3+ differentiation in naive T cells. Furthermore, GR- or AR-biding re-
gions have been identified in FoxP3+, which may modulate the activities of FoxP3+Treg
cells [41,42]. However, functional studies to better understand the molecular mechanisms
associated with the triple dominant subgroup of EOC are necessary. In addition, we plan to
incorporate larger numbers of specific histological subgroups to generalize our findings, as
we did not find a significant difference in prognosis in the triple dominant group depending
on FoxP3+ expression, which is a limitation of our study.
The TNF and/or the NF-κB signaling pathways are key regulators of innate and
adaptive immune responses, functioning to regulate cell death and survival [36,43]. RELA
is a subunit of the NF-κB signaling pathway, while MAP3K5 functions as a positive
regulator by phosphorylating IKKβ. Moreover, BCL2L1, RIPK1, TRAF2, PARP1, and AKT1
are protooncogenes upregulated by the NF-κB signaling pathway. Additionally, TNFAIP3
is an antiapoptotic gene with a rapidly upregulated expression upon activation of the
TNF and/or NF-κB signaling pathway [36,44]. Furthermore, TNFAIP3 is constitutively
expressed by T and B cells to inhibit Treg lymphocytes and hyperactivate Th and cytotoxic
T cells [44,45]. However, in EOC, the role of TNFAIP3 remains controversial. Therefore,
future studies should evaluate its role in EOC and incorporate the role of TNFAIP3 with
the triple dominant subgroup of EOC to identify its potential as a prognostic or therapeutic
target.
Lastly, as the abundance of Tregs and their functionality have been associated with
steroid hormone receptors, reducing the expression of these receptors could subsequently
reduce the Treg population, which may improve patient survival. Generail et al. [46,47]
performed a phase II randomized controlled trial of letrozole with, or without, the im-
munomodulatory agent cyclophosphamide in patients with breast cancer. Results showed
a significant reduction of Treg number and a significant correlation between the reduced
number of Tregs and the number of patients who achieved complete remission when
treated with letrozole in combination with cyclophosphamide, as estrogen was shown
to increase Treg number and functionality. Therefore, in the triple dominant subgroup,
inhibiting AR, PR, and GR via combination immunotherapy may improve the number of
patients with EOC achieving complete remission.
In conclusion, we identified an EOC subgroup based on hormone receptor expression
that displays prognostic significance. Moreover, our newly constructed EOC subgroup
classification revealed important TIL features. Although additional studies are necessary to
clarify the underlying mechanism, our newly classified triple dominant EOC subgroup has
prognostic and predictive value. Overall, the proposed hormone receptor expression-based
classification may contribute to precision medicine development in EOC and determine
the most efficient therapeutic course.
4. Materials and Methods
4.1. Patients and Tumor Specimens
A total of 212 EOC, 57 borderline ovarian tumor, 153 benign epithelial ovarian tumors
and 79 nonadjacent normal epithelial tissue samples were obtained from patients who
underwent primary surgery at the Gangnam Severance Hospital between 2004 and 2012,
and some of the samples were obtained from the Korea Gynecologic Cancer Bank as
part of the Bio and Medical Technology Development Program of the Ministry of the
National Research Foundation (NRF), funded by the Korean government (MIST) (NRF-
2017M3A9B8069610). The International Federation of Gynecology and Obstetrics (FIGO)
classification was used for tumor staging, and clinical information, including surgical
procedure, survival time, survival status, and age, were collected by reviewing the medical
records of the patients. The patients’ response to therapy was assessed by using computed
tomography with Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1).
Tumor grade and cell type were evaluated by reviewing pathological reports, and all tumor
samples were histologically examined by two gynecologic pathologists. All biological
samples were collected after obtaining informed consent from participants, following the
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guidelines of the institutional review board (IRB) of the Gangnam Severance Hospital (IRB
No. 3-2018-0122).
4.2. Tissue Microarray and Immunohistochemistry
Tissue microarray (TMA) blocks comprising tissue cores (1 mm) with a sufficient
proportion of tumor cells obtained from formalin-fixed paraffin-embedded (FFPE) tumor
tissue blocks were used for immunohistochemistry (IHC) analysis of ERα, AR, glucocor-
ticoid receptor (GR), PR, ERβ, PD-1, and PD-L1 (5-µm-thick sections cut using a rotary
microtome), whereas whole tissue sections were used for the IHC analysis of CD4+, CD8+,
CD3+, and FoxP3+. The sections were deparaffinized and rehydrated with graded ethanol.
Then, the sections were treated with 3% H2O2 solution in methanol for 30 min to suppress
endogenous peroxidase activity. Thereafter, heat-induced antigen retrieval was performed
by incubating the sections in a target retrieval buffer at pH 6.0 (Dako, Carpinteria, CA,
USA) using a steam pressure cooker (Pascal; Dako) for 20 min, and the slides were stained
with the primary antibodies listed in Supplementary Table S5 with Autostainer Plus (Dako)
for 1 h at room temperature. Then, EnVision+ Dual Link System-HRP (Dako) and DAB+
(3,3′-diaminobenzidine; Dako) were used for the visualization of antigen-antibody reac-
tions. After dehydrating and counterstaining with hematoxylin, the slides were mounted
in Faramount Aqueous Mounting Medium (Dako). Proper positive and negative controls
were included.
4.3. Evaluation of Immunohistochemical (IHC) Staining
The stained TMA sections were scanned with a high-resolution optical scanner
(NanoZoomer 2.0 HT; Hamamatsu Photonics K.K., Hamamatsu City, Japan) at 20× ob-
jective magnification (0.5 µm resolution). In the case of ERα, AR, GR, PR, and ERβ, the
scanned sections were analyzed using Visiopharm software, version 4.5.1.324 (VIS; Vi-
siopahrm, Hϕrsholm, Denmark). Two hundred and seven EOC, 56 borderline ovarian
tumor, 110 benign tumor, and 79 nonadjacent normal epithelial tissues for ERα expression;
192 EOC, 55 borderline ovarian tumor, 111 benign tumor, and 79 nonadjacent normal
epithelial tissues for AR expression; 208 EOC, 54 borderline ovarian tumor, 112 benign
tumor, and 78 nonadjacent normal epithelial tissues for PR expression; 209 EOC, 57 bor-
derline ovarian tumor, 123 benign tumor, and 79 nonadjacent normal epithelial tissues
for GR expression; and 205 EOC, 55 borderline ovarian tumor, 108 benign tumor, and 79
nonadjacent normal epithelial tissues for ERβ expression were analyzed using the TMA.
The staining intensity was scored semi-quantitatively using the immunoreactive score
(IRS) with a predefined algorithm and settings. The IRS was obtained as the product of
immunostaining intensity (0 = negative, 1 = weak, 2 = moderate, 3 = strong), while the
overall immunostaining score was calculated by multiplying the percentage of positive
cells and immunostaining intensity (possible range: 0–300). For PD-1 and PD-L1 scoring,
tumor areas were automatically outlined, followed by manual editing to exclude necrotic
tissues, and PD-1 and PD-L1 levels were quantified by analyzing the percentage of DAB+
using Visiopharm software version 4.5.1.324 (VIS; Visiopharm). Lastly, TILs were eval-
uated following the recommendation of the International TILs Working Group [48]. Six
independent regions of interest (ROI with the highest TIL numbers, comprising 2 mm2
stromal areas with the highest number of TILs from entire tumor sections, were selected
and evaluated for TILs using Visiopharm software version 4.5.1.324 (VIS; Visiopharm). The
area for stromal TIL evaluation was set within the invasive tumor borders that did not
include immune infiltration in the adjacent normal tissue of EOCs. Additionally, mononu-
clear stromal cells which were not directly contacting with cancer cells were considered
stromal TILs. Positive staining was assessed quantitatively, and the results expressed as a
percentage of positively stained area relative to the total ROI. The results for each section’s
ROIs were then averaged.
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4.4. mRNA-seq Data Analysis
The gene expression profiling data consisting of 185 primary ovarian tumors and
10 normal ovarian surface epithelia profiled by using the Affymetrix human U133A microar-
ray were downloaded from the gene expression omnibus (GEO) data (http://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE26712, GSE26712, accessed on 30 April 2021).
4.5. RNA Extraction and Quality Control
FFPE slides of normal ovarian epithelial tissues and EOCs were stained with hema-
toxylin and eosin to identify and mark normal ovarian epithelial tissues and EOC regions
by a gynecological pathologist. In the case of EOC, FFPE sections consisting of more than
85% tumor cells within each specimen were subjected to laser-capture microdissection
(LCM). After sectioning FFPE tissues, they were placed on slides coated with polyethylene
terephthalate membrane (Leica Microsystems Inc., IL, USA), and LCM was performed
using the Leica AS LMD laser microdissection system (Leica Microsystems Inc.) following
the manufacturer’s instructions. Total RNA was extracted using the RNeasy FFPE kit
(Qiagen, Valencia, CA), according to the manufacturer’s instructions. RNA concentration
was quantified using a Nanodrop spectrophotometer (Thermo Scientific, Waltham, MA,
USA), and its quality was verified on formaldehyde agarose gels.
4.6. Quantification of Gene Expression and Analysis of Differentially Expressed Genes (DEGs)
Using the NanoString nCounter Platform
Three hundred nanograms of isolated RNA from each sample were used for hybridiza-
tion with the PanCancer IO 360 Panel Gene Expression Panel (NanoString Technologies,
Inc., Seattle, WA, USA), according to the manufacturer’s instructions and transferred to the
Digital Analyzer (NanoString Technologies, Inc.) for analysis. After background correction,
gene expression was normalized using the target to housekeeping gene expression ratio,
with nSolver Analysis Software version 4.0 (NanoString Technologies, Inc.). Finally, DEGs
between the normal ovarian epithelial tissues and EOCs were log2 transformed. Group
analyses for DEGs were performed using in-house R scripts. The scatter plots for the gene
expression values, volcano plots for the expression fold-changes, and p-values between the
two selected samples were similarly calculated using in-house R scripts.
4.7. Network Analysis
To construct the ovarian tissue-specific protein-protein interaction (PPI) network with
the minimum- or zero-order network model, 169 upregulated DEGs were used as an
input for network analyst (https://www.networkanalyst.ca/, accessed on 15 December
2020) [25].
4.8. Gene Ontology Analysis
All the genes listed in the Nanostring analysis were used to perform g:profiler
(https://biit.cs.ut.ee/gprofiler/gost, accessed on 30 April 2021) with default parameters
to investigate the affected pathways [26]. The analyzed parameters for the statistical do-
main scope included “g:SCS threshold” for the significance threshold and 0.05 as a user
threshold, and the statistical domain scope was set as custom.
4.9. Statistical Analysis
Statistical analyses of hormone receptors, TILs, PD-1, and PD-L1 expression data
were performed using either Mann–Whitney U-test or Kruskal–Wallis test, as appropriate.
Kaplan–Meier method was used to assess disease-free survival (DFS) and overall survival
(OS). Survival was analyzed using the log-rank test with the cut-off values that had the
highest discriminative power. A clustering analysis was performed to identify EOC samples
with similar hormone receptor expression patterns. Cox proportional hazards model was
used to estimate the hazard ratios (HR) and confidence intervals (CIs) in both univariate
and multivariate models. Statistical analyses were performed using either SPSS version
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25.0 (SPSS, Chicago, IL) or R software (version 3.6.3). Results with a p-value < 0.05 were
considered statistically significant.
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